-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160

Benzinga·09/29/2026 17:56:14
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.